Roquefort Therapeutics plc (LON: ROQ)

London flag London · Delayed Price · Currency is GBP · Price in GBX
3.600
-0.200 (-5.26%)
Jan 23, 2025, 8:13 AM BST
-46.67%
Market Cap 5.16M
Revenue (ttm) n/a
Net Income (ttm) -1.54M
Shares Out 135.74M
EPS (ttm) -0.01
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 135,883
Average Volume 1,094,014
Open 3.620
Previous Close 3.800
Day's Range 3.600 - 3.620
52-Week Range 3.300 - 9.500
Beta -0.27
RSI 45.50
Earnings Date Dec 27, 2024

About Roquefort Therapeutics

Roquefort Therapeutics plc, a material biotech company, engages in the development of medicines for the treatment of cancer. Its product portfolio consists of five novel patent-protected pre-clinical anti-cancer medicines, which include Midkine antibodies with significance in vivo efficacy, toxicology studies, and orphan drug indication; Midkine RNA oligonucleotide therapeutics with novel anti-cancer gene editing action; Midkine mRNA therapeutics for solid tumors; STAT-6 siRNA therapeutics targeting solid tumors with significance in vivo effica... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2020
Employees 10
Stock Exchange London Stock Exchange
Ticker Symbol ROQ
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.